Aurinia Pharmaceuticals has announced a definitive agreement to acquire Kezar Life Sciences, a clinical-stage biotechnology company. The deal is structured with an upfront payment of $6.955 in cash per share plus a non-transferable contingent value right (CVR) for future milestones. This strategic acquisition significantly expands Aurinia's pipeline with the addition of zetomipzomib, a promising first-in-class therapeutic for autoimmune diseases.
Strategic Rationale and Key Asset
At the center of the acquisition is zetomipzomib, Kezar’s lead product candidate for autoimmune hepatitis, lupus nephritis, and systemic lupus erythematosus. As a first-in-class immunoproteasome inhibitor, it demonstrated clinically meaningful and durable remissions in a Phase 2 study. Kezar also recently held positive discussions with the FDA to accelerate the drug's development path in autoimmune hepatitis.
The Kezar board of directors unanimously approved the transaction, determining it to be in the best interests of its stockholders following a strategic review. Chris Kirk, Kezar's CEO, expressed confidence that Aurinia is well-positioned to advance the novel therapeutic agent. Aurinia's established track record in developing and commercializing treatments for autoimmune diseases makes it an ideal partner for zetomipzomib's next phase.
Transaction Details and Shareholder Support
The deal's financial structure offers Kezar shareholders both immediate and potential long-term value. The CVR entitles holders to payments related to zetomipzomib's clinical development or disposition, as well as proceeds from other Kezar collaborations. It also includes 100% of Kezar’s closing net cash that exceeds a $50 million threshold, net of certain expenses.
Aurinia will initiate a tender offer by April 13, 2026, to acquire all outstanding shares of Kezar common stock. The transaction's closing is contingent upon several conditions, including the tender of a majority of Kezar's outstanding shares. Another key condition requires Kezar to maintain closing net cash of over $50 million, with the deal expected to close in the second quarter of 2026.
The acquisition has already secured significant backing from a key institutional investor, signaling strong market confidence. Tang Capital Partners, which holds approximately 9.0% of Kezar's outstanding common stock, has formally agreed to tender its shares. This support agreement provides early momentum for the successful completion of the tender offer and subsequent merger.
Aurinia's Corporate Momentum
This acquisition follows a period of strong financial performance for Aurinia Pharmaceuticals, positioning the company for strategic growth. The company recently reported fourth-quarter 2025 results that significantly surpassed analyst expectations, with earnings per share of $1.53 against a projection of $0.15. Revenue also exceeded forecasts, reaching $77.1 million and highlighting robust operational execution.
Aurinia has also undergone a significant leadership transition ahead of this strategic move. The company recently appointed board chair Kevin Tang as its new Chief Executive Officer, who will notably serve without a salary, bonus, or equity awards. This change followed the departure of the former CEO, marking a new chapter for the company's executive team as it pursues expansion.
Ultimately, the acquisition of Kezar Life Sciences represents a pivotal strategic move for Aurinia Pharmaceuticals, bolstering its portfolio in the competitive autoimmune disease landscape. The transaction delivers immediate cash value to Kezar shareholders while providing continued participation in the potential success of zetomipzomib through the CVR. This deal leverages Aurinia's recent financial and leadership momentum to accelerate the development of a promising new therapy for patients.